Full Year Total Revenue of $283.5 million Full Year Core Revenue grows 7% year-over-year to $281.2 million Ended 2024 with $828.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.87 EL MONTE, Calif. / Feb 28, 2025 / Business Wire / Fulgent Genetics, Inc . (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a... Read More

EL MONTE, Calif. / Feb 06, 2025 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 28, 2025. Management will host a conference call for... Read More

Total Revenue of $71.7 million Core Revenue grows 9% year-over-year to $71.7 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 EL MONTE, Calif. / Nov 08, 2024 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development... Read More

EL MONTE, Calif. / Nov 05, 2024 / Business Wire / Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences: UBS Global Healthcare Conference on Tuesday, November 12th at... Read More

EL MONTE, Calif. / Oct 31, 2024 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has been awarded a five-year contract by the U.S. Department of Veterans Affairs (VA) to provide hereditary cancer, pharmacogenetic and other genetic testing to Veterans.... Read More

EL MONTE, Calif. / Oct 17, 2024 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Management will host a conference call for the investment... Read More

Total Revenue of $71.0 million Core Revenue grows 5% year-over-year to $70.2 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 EL MONTE, Calif. / Aug 02, 2024 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development... Read More

EL MONTE, Calif. / Jul 11, 2024 / Business Wire / Fulgent Genetics, Inc. ( NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results before the market opens on Friday, August 2, 2024. Management will host a conference call for the investment... Read More

EL MONTE, Calif. / Jun 03, 2024 / Business Wire / Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, was presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on June... Read More

EL MONTE, Calif. / May 24, 2024 / Business Wire / Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on... Read More

Collaboration aims to accelerate the development of personalized therapies and transform patient care through the use of precision medicine TAMPA, Fla. & LOS ANGELES / May 14, 2024 / Business Wire / Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc . (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer... Read More

Total Revenue of $64.5 million Core Revenue grows 1% year-over-year to $63.2 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million EL MONTE, Calif. / May 03, 2024 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for... Read More

EL MONTE, Calif. / Apr 11, 2024 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024. Management will host a conference call for the investment... Read More

Full Year 2023 Total Revenue of $289.2 million; Q4 2023 Total Revenue of $70.5 million Full Year 2023 Core Revenue grows 44% year-over-year to $262.1 million; Q4 2023 Core Revenue grows 21% year-over-year to $66.5 million Ended 2023 with $847.7 million of cash, cash equivalents, and investments in marketable securities, representing cash per share of $28 EL MONTE, Calif. / Feb 28, 2024 / Business Wire / Fulgent Genetics,... Read More

EL MONTE, Calif. / Feb 13, 2024 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 28, 2024. Management will host a conference call... Read More

EL MONTE, Calif. / Nov 14, 2023 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate in the Piper Sandler 35 th Annual Healthcare Conference on Tuesday, November 28, 2023. These representatives... Read More

EL MONTE, Calif. / Nov 03, 2023 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced data from two poster presentations being presented tomorrow, November 4, 2023, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA. “These... Read More

Core Revenue of $66 million represents Growth of 17% Year-over-Year Additional Reimbursement from COVID-19 Test Sales yields Revenue of $19 million, for Total Revenue of $85 million Reiterates Full Year 2023 Core Revenue Guidance of $260 million EL MONTE, Calif. / Nov 03, 2023 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical... Read More

EL MONTE, Calif. / Oct 25, 2023 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from... Read More

EL MONTE, Calif. / Oct 17, 2023 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its third quarter 2023 financial results before the market opens on Friday, November 3, 2023. Management will host a conference call for the investment... Read More

Total Revenue of $68 million Record Core Revenue of $67 million, growth of 48% year-over-year Raises Full Year 2023 Core Revenue Guidance to $260 million and Narrows Expected Loss EL MONTE, Calif. / Aug 04, 2023 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today... Read More

EL MONTE, Calif. / Jul 18, 2023 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its second quarter 2023 financial results before the market opens on Friday, August 4, 2023. Management will host a conference call for the investment... Read More

EL MONTE, Calif. / Jun 05, 2023 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced data from a Phase 1/1b clinical study of FID-007 in treating various solid tumors was presented in a poster session at the American Society for Clinical Oncology (ASCO)... Read More

EL MONTE, Calif. / May 18, 2023 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that Phase 1/1b clinical data on its lead therapeutic development candidate, FID-007, to treat various solid tumors, will be presented at the American Society for Clinical... Read More

Total Revenue of $66.2 million Record Core Revenue of $62.7 million, growth of 150% year-over-year Raises Full Year 2023 Core Revenue Guidance to $250 million EL MONTE, Calif. / May 05, 2023 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial... Read More

TEMPLE CITY, Calif. / Apr 20, 2023 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its first quarter 2023 financial results before the market opens on Friday, May 5, 2023. Management will host a conference call for the investment... Read More

Strategic partnership between Mission Bio and Fulgent Genetics will enable drug developers to leverage single-cell multi-omics for biomarker discovery, clinical research, and single-cell MRD development at scale SOUTH SAN FRANCISCO, Calif. , April 11, 2023 /PRNewswire/ -- Mission Bio, Inc. , the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced that it has entered into an agreement with... Read More

TEMPLE CITY, Calif. / Feb 23, 2023 / Business Wire / Fulgent, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate in the Raymond James & Associates’ 44 th Annual Institutional Investors Conference on Tuesday, March 7, 2023. These... Read More

TEMPLE CITY, Calif. / Feb 14, 2023 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced that it will release its fourth quarter and full year 2022 financial results after the market closes on Tuesday,... Read More

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of Reggie Groves to its board of directors, effective January 3, 2023. “Reggie possesses a diverse business skill set and a global perspective that we believe will be invaluable to Fulgent’s Board of Directors, as we enter a new chapter in precision medicine with our recent acquisition of Fulgent Pharma,” said... Read More